Libervant was approved in April 2024. AQST’s lead pipeline asset is Anaphylm, a Sublingual Epinephrine Film for the treatment of Type 1 allergic reactions, including anaphylaxis. This film uses ...
Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback